Anti-human cd52 immunoglobulins

Abstract

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

1 . (canceled) 
     
     
         2 . A monoclonal anti-human CD52 antibody, or an antigen-binding portion thereof, that binds to the same epitope on human CD52 as an anti-human CD52 antibody whose light chain and heavy chain comprise the three complementarity determining regions (CDRs) found in
 a) SEQ ID NOs: 3 and 16, respectively   b) SEQ ID NOs: 4 and 17, respectively;   c) SEQ ID NOs: 5 and 18, respectively;   d) SEQ ID NOs: 6 and 19, respectively;   e) SEQ ID NOs: 7 and 20, respectively;   f) SEQ ID NOs: 8 and 21, respectively;   g) SEQ ID NOs: 9 and 22, respectively;   h) SEQ ID NOs: 10 and 23, respectively;   i) SEQ ID NOs: 11 and 24, respectively;   j) SEQ ID NOs: 12 and 25, respectively;   k) SEQ ID NOs: 12 and 137, respectively; or   l) SEQ ID NOs: 13 and 26, respectively.   
     
     
         3 . A monoclonal anti-human CD52 antibody, or an antigen-binding portion thereof, that competes or cross-competes with an anti-human CD52 antibody whose light chain and heavy chain comprise the three complementarity determining regions (CDRs) found in
 a) SEQ ID NOs: 3 and 16, respectively;   b) SEQ ID NOs: 4 and 17, respectively;   c) SEQ ID NOs: 5 and 18, respectively;   d) SEQ ID NOs: 6 and 19, respectively;   e) SEQ ID NOs: 7 and 20, respectively;   f) SEQ ID NOs: 8 and 21, respectively;   g) SEQ ID NOs: 9 and 22, respectively;   h) SEQ ID NOs: 10 and 23, respectively;   i) SEQ ID NOs: 11 and 24, respectively;   i) SEQ ID NOs: 12 and 25, respectively;   k) SEQ ID NOs: 12 and 137, respectively; or   l) SEQ ID NOs: 13 and 26, respectively.   
     
     
         4 - 24 . (canceled) 
     
     
         25 . An isolated nucleic acid encoding the heavy chain or an antigen-binding portion thereof, or the light chain or an antigen-binding portion thereof, of the monoclonal antibody of  claim 2 . 
     
     
         26 - 28 . (canceled) 
     
     
         29 . A recombinant vector comprising (1) a nucleic acid sequence encoding the heavy chain or an antigen-binding portion thereof, (2) a nucleic acid sequence encoding the light chain or an antigen-binding portion thereof, or (3) both, of a monoclonal antibody according to  claim 2 . 
     
     
         30 . A host cell comprising a first nucleic acid sequence encoding the heavy chain or an antigen-binding portion thereof of a monoclonal antibody according to  claim 2 , said first nucleic acid sequence operably linked to an expression control element, and a second nucleic acid sequence encoding the light chain or an antigen-binding portion thereof of said monoclonal antibody, said second nucleic acid sequence operably linked to an expression control element. 
     
     
         31 . A method of making an anti-human CD52 antibody or an antigen-binding portion thereof, comprising maintaining the host cell of  claim 30  under conditions appropriate for expression of the antibody or portion. 
     
     
         32 . (canceled) 
     
     
         33 . A composition comprising the monoclonal antibody or antigen-binding portion according to  claim 2  and a pharmaceutically acceptable vehicle or carrier. 
     
     
         34 . A method for treating a patient in need thereof, comprising administering to the patient an effective amount of the monoclonal antibody or antigen-binding portion according to  claim 2 . 
     
     
         35 - 54 . (canceled) 
     
     
         55 . An isolated nucleic acid encoding the heavy chain or an antigen-binding portion thereof, or the light chain or an antigen-binding portion thereof, of the monoclonal antibody of  claim 3 . 
     
     
         56 . A recombinant vector comprising (1) a nucleic acid sequence encoding the heavy chain or an antigen-binding portion thereof, (2) a nucleic acid sequence encoding the light chain or an antigen-binding portion thereof, or (3) both, of a monoclonal antibody according to  claim 3 . 
     
     
         57 . A host cell comprising a first nucleic acid sequence encoding the heavy chain or an antigen-binding portion thereof of a monoclonal antibody according to claim  3 , said first nucleic acid sequence operably linked to an expression control element, and a second nucleic acid sequence encoding the light chain or an antigen-binding portion thereof of said monoclonal antibody, said second nucleic acid sequence operably linked to an expression control element. 
     
     
         58 . A method of making an anti-human CD52 antibody or an antigen-binding portion thereof, comprising maintaining the host cell of  claim 57  under conditions appropriate for expression of the antibody or portion. 
     
     
         59 . A composition comprising the monoclonal antibody or antigen-binding portion according to  claim 3  and a pharmaceutically acceptable vehicle or carrier. 
     
     
         60 . A method for treating a patient in need thereof, comprising administering to the patient an effective amount of the monoclonal antibody or antigen-binding portion according to  claim 3 .